Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Aug
23
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo